Summary: Featuring articles on ocrelizumab in primary progressive multiple sclerosis, ocrelizumab vs. interferon beta-1a in relapsing MS, a "zombie" outbreak caused by a synthetic cannabinoid, extensively drug-resistant tuberculosis, and immunity to Mycobacterium tuberculosis; a review article on obesity; a case report of a woman with acute liver failure; and Perspective articles on transparency and trust, on population health, on cost-effectiveness analysis 2.0, and on the psychocatalytic benefits of the unexpected.
